CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 2,228.00
+27.20 (1.24%)
Last updated: Sep 11, 2026, 3:29 PM IST
CORONA Remedies Revenue
CORONA Remedies had revenue of 4.22B INR in the quarter ending June 30, 2026, with 21.90% growth. This brings the company's revenue in the last twelve months to 14.79B, up 19.24% year-over-year. In the fiscal year ending March 31, 2026, CORONA Remedies had annual revenue of 14.03B with 17.28% growth.
Revenue (ttm)
14.79B
Revenue Growth
+19.24%
P/S Ratio
9.25
Revenue / Employee
2.87M
Employees
5,153
Market Cap
136.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 14.03B | 2.07B | 17.28% |
| Mar 31, 2025 | 11.96B | 1.82B | 17.94% |
| Mar 31, 2024 | 10.14B | 1.30B | 14.75% |
| Mar 31, 2023 | 8.84B | 2.67B | 43.21% |
| Mar 31, 2022 | 6.17B | 411.66M | 7.14% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Apollo Hospitals Enterprise | 264.30B |
| Divi's Laboratories | 112.30B |
| Lenskart Solutions | 96.34B |
| Indegene | 38.13B |
| Syngene International | 36.00B |
| NATCO Pharma | 34.85B |
| Marksans Pharma | 31.72B |
CORONA Remedies News
- 13 days ago - CORONA Remedies Transcript: Transcript - Transcripts
- 13 days ago - CORONA Remedies Transcript: Transcript - Transcripts
- 20 days ago - CORONA Remedies Annual report - Filings
- 8 months ago - CORONA Remedies Transcript: Q2 25/26 - Transcripts
- 8 months ago - CORONA Remedies Quarterly report: Q2 2026 - Filings
- 8 months ago - CORONA Remedies Slides: Q2 2026 - Filings